BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25675103)

  • 1. IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients.
    Bordi L; Caglioti C; Garbuglia AR; Lapa D; Castilletti C; Taibi C; Capobianchi MR; Lalle E
    PLoS One; 2015; 10(2):e0117397. PubMed ID: 25675103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-Alpha receptor-1 upregulation in PBMC from HCV naïve patients carrying cc genotype. possible role of IFN-lambda.
    Lalle E; Bordi L; Caglioti C; Garbuglia AR; Castilletti C; Taibi C; Cristofari F; Capobianchi MR
    PLoS One; 2014; 9(4):e93434. PubMed ID: 24691098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
    J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.
    Knapp S; Zakaria Z; Hashem M; Zaghla H; Khakoo SI; Waked I; Thursz M; Abdelwahab SF
    Hepatol Int; 2015 Apr; 9(2):251-7. PubMed ID: 25788203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
    PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
    Thong VD; Wasitthankasem R; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
    PLoS One; 2015; 10(5):e0125400. PubMed ID: 25938236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
    Grzegorzewska AE; Mostowska A; Świderska MK; Marcinkowski W; Stolarek I; Figlerowicz M; Jagodziński PP
    BMC Infect Dis; 2021 Jan; 21(1):102. PubMed ID: 33482747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
    Wu R; Chi X; Wang X; Sun H; Lv J; Gao X; Yu G; Kong F; Xu H; Hua R; Jiang J; Sun B; Zhong J; Pan Y; Niu J
    Infect Genet Evol; 2016 Apr; 39():132-140. PubMed ID: 26820907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms.
    Nafari AH; Ayadi A; Noormohamadi Z; Sakhaee F; Vaziri F; Siadat SD; Fateh A
    Infect Genet Evol; 2020 Apr; 79():104144. PubMed ID: 31838260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population.
    Huang P; Yao Y; Yue M; Tian T; Chen H; Chen M; Wang J; Zhang Y; Yu R
    Sci Rep; 2017 Feb; 7():42408. PubMed ID: 28186161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
    J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples.
    Amanzada A; Kopp W; Spengler U; Ramadori G; Mihm S
    PLoS One; 2013; 8(12):e84026. PubMed ID: 24376784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
    Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.
    Amanzada A; Reinhardt L; Fey D; Zeisberg EM; Mihm S
    PLoS One; 2015; 10(11):e0143783. PubMed ID: 26606750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
    Franco S; Aparicio E; Parera M; Clotet B; Tural C; Martinez MA
    AIDS; 2014 Jan; 28(1):133-6. PubMed ID: 24072198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C.
    Imoto S; Kim SR; Amano K; Iio E; Yoon S; Hirohata S; Yano Y; Ishikawa T; Katsushima S; Komeda T; Fukunaga T; Chung H; Kokuryu H; Horie Y; Hatae T; Fujinami A; Kim SK; Kudo M; Tanaka Y
    Dig Dis; 2017; 35(6):531-540. PubMed ID: 29040985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.